March 12, 2021 Decades of Pain and Uncertainty: Donna’s AHP Story For more than 20 years, Donna navigated debilitating pain, mysterious symptoms and uncertainty about her health. Today, with a better handle on her wellbeing Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend to Read More ›
March 2, 2021 When Are Kidney Stones a Red Flag? According to some estimates, every 1 in 10 adults in the U.S. experiences a kidney stone, suggesting that kidney stones can be rather prevalent. But when are st Read More ›
February 23, 2021 Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud. While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those impacted Read More ›
February 6, 2021 Alnylam Named to Bloomberg's 2021 Gender-Equality Index Alnylam has been selected to Bloomberg's Gender-Equality Index for 2021 Read More ›
December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
November 20, 2020 6 in a Row! Alnylam Named a Boston Globe Top Place to Work for 2020 Alnylam has been named to The Boston Globe's Top Places to Work list for 2020, marking 6th years in a row. Read More ›
November 5, 2020 My Journey to an AHP Diagnosis: Claire and Candace Claire and Candace share their stories of their long journeys to an acute hepatic porphyria (AHP) diagnosis. Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site